Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GYS1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Glycogen synthase 1 (GYS1) also known as muscle glycogen synthase catalyzes the synthesis of glycogen from glucose. It adds glucose units from UDP-glucose to the non-reducing ends of glycogen chains facilitating glycogen elongation. The molecular mass of GYS1 is approximately 85 kDa. It is predominantly expressed in skeletal muscle tissue providing energy storage primarily in the form of glycogen. GYS1 is regulated through phosphorylation wherein it undergoes inactive to active conformational changes.
Biological function summary
This enzyme plays a critical role in the energy storage mechanism of muscle tissues. GYS1 functions as a part of the glycogen synthase complex interacting with various glycogen-associated proteins to modulate its activity. These interactions control the enzyme's affinity for its substrate and its susceptibility to regulatory signals like phosphorylation affecting glycogen synthesis efficiency. Through its activity GYS1 ensures a readily available reserve of glucose in muscle tissues for rapid energy production when required.
Pathways
Glycogen synthase 1 is a central component of the glycogen metabolism pathway. It acts alongside other enzymes such as glycogen phosphorylase which catalyzes glycogen breakdown. The balance between GYS1 and glycogen phosphorylase determines the rate of glycogen turnover within cells. GYS1 is further regulated by the insulin signaling pathway where insulin promotes glycogen synthesis by altering GYS1 activity alongside proteins like AKT influencing glucose homeostasis and energy management in tissues.
Dysregulation of GYS1 activity often associates with glycogen storage diseases notably Type 0 where deficiencies in glycogen storage lead to episodes of low blood sugar and reduced exercise capacity. Furthermore aberrations in GYS1 function contribute to insulin resistance and Type 2 diabetes conditions linked with impaired glucose metabolism. Altered GYS1 activity impacts proteins like glycogen phosphorylase affecting overall glycogen metabolism balance and contributing to metabolic disorders.
